Evaluation of Fractional Ablative Laser Treatment for Skin Conditions

Skin Laxity Clinical Trial

Official title:

Pilot Evaluation of Fractional Ablative Laser Treatment for Skin Laxity and Tightening

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05750901
• Other study ID #: LC-001
• Status: Recruiting
• Phase: N/A
• Start date: November 1, 2022
• Est. completion date: January 20, 2025

Study information

• Verified date: April 2024
• Source: Sciton
• Contact: Sciton Inc.
• Phone: 6504939155
• Email: clinicaltrials[@]sciton.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the safety and efficacy of the fractional ablative laser for treatment of skin laxity and tightening

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: January 20, 2025
• Est. primary completion date: December 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects aged 18-85 years

2. Fitzpatrick skin type I-VI

3. Has visible skin laxity in the treatment region or has a scar

4. Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant for the duration of the study (Applicable to female subjects only)

5. Willing to have digital imaging and measurements taken of the treatment area and agree to use for presentation, educational or marketing purposes

6. Subject must be able to read, understand and sign Informed Consent Form in English

7. Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions

Exclusion Criteria:

1. Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.

2. Any type of prior cosmetic treatment to the target area at physicians' discretion

3. History of malignant tumors in the target area.

4. Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, large moles.

5. Pregnant and/or breastfeeding (Applicable to females only)

6. Having an infection, dermatitis or a rash in the treatment area.

7. Significant concurrent illness, such as diabetes mellitus, cardiovascular disease, e.g., uncontrolled hypertension or pertinent neurological disorders.

8. Suffering from coagulation disorders or taking prescription anticoagulation medications.

9. History of keloid scarring, hypertrophic scarring or of abnormal wound healing.

10. History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.

11. History of vitiligo, eczema, or psoriasis.

12. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.

13. History of radiation to the treatment area or undergoing systemic chemotherapy for the treatment of cancer.

14. Current smoker or history of smoking within 6 months of study participation.

15. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study

Related Conditions & MeSH terms

• Cutis Laxa
• Skin Laxity

Intervention

Device:
• Fractional ablative laser
Fractional ablative laser used for treatment for skin laxity and tightening

Locations

Country	Name	City	State
United States	Sanctuary Plastic Surgery	Boca Raton	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Sciton

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Wrinkles	Percent improvement in wrinkles will be assessed using digital camera at baseline and post final treatment.	1-6 months post final treatment